发明名称 COMPLEX GRANULE FORMULATION HAVING IMPROVED STABILITY COMPRISING LEVOCETIRIZINE AND MONTELUKAST
摘要 The present invention relates to a complex granule formulation comprising a first granular part comprising levocetirizine or its pharmaceutically acceptable salt, cyclodextrin or its derivative, and an alkalinizing agent; and a second granular part comprising montelukast or its pharmaceutically acceptable salt, cyclodextrin or its derivative, and an alkalinizing agent. This formulation can effectively inhibit the production of related compounds of levocetirizine and montelukast by allowing levocetirizine and montelukast to form clathrate complexes with cyclodextrin, and using an alkalinizing agent. This formulation not only shows increased stability and bioavailability, but also improves patient compliance owing to its effective masking of bitter taste.
申请公布号 US2016367551(A1) 申请公布日期 2016.12.22
申请号 US201414898935 申请日期 2014.06.16
申请人 HANMI PHARM. CO., LTD 发明人 IM Ho Taek;KWON Taek Kwan;KIM Yong Il;PARK Jae Hyun;WOO Jong Soo
分类号 A61K31/495;A61K31/47;A61K9/16 主分类号 A61K31/495
代理机构 代理人
主权项 1. A complex granule formulation comprising: (a) a first granular part comprising levocetirizine or a pharmaceutically acceptable salt thereof, cyclodextrin or a derivative thereof, and an alkalinizing agent; and (b) a second granular part comprising montelukast or a pharmaceutically acceptable salt thereof, cyclodextrin or a derivative thereof, and an alkalinizing agent.
地址 Hwaseong-si, Gyeonggi-do KR